NVDA
NVIDIA
-- 144.470 TSLA
Tesla
-- 410.440 PLTR
Palantir
-- 79.890 CRNC
Cerence
-- 19.330 MSTR
MicroStrategy
-- 339.660 
NEWS
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
Thursday, 2nd January at 8:00 pm
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to provide updated Phase 2 data for subcutaneous lonigutamab further supporting its potential for a best-in-class efficacy and safety profile in Thyroid Eye Disease (TED). The event will also feature external clinician perspectives on the continuing unmet needs in TED and disclose the design for the Phase 3 LONGITUDE program, which was developed following a successful End-of-Phase 2 meeting with the FDA to be the most inclusive registrational program to date in TED. To register, click here.
ACELYRIN Chief Executive Officer Mina Kim, Chief Medical Officer Dr. Shep Mpofu and Chief Commercial Officer Ken Lock will be joined by Drs. Andrea Kossler of the Stanford University School of Medicine and Prem Subramanian of the University of Colorado School of Medicine, both members of ACELYRIN's Scientific and Patient Advisory Boards. A live question and answer session will follow the formal presentations and a recording of the webcast will be available and archived on the Company's website for approximately 30 days.
Thursday, 2nd January at 8:00 pm
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to provide updated Phase 2 data for subcutaneous lonigutamab further supporting its potential for a best-in-class efficacy and safety profile in Thyroid Eye Disease (TED). The event will also feature external clinician perspectives on the continuing unmet needs in TED and disclose the design for the Phase 3 LONGITUDE program, which was developed following a successful End-of-Phase 2 meeting with the FDA to be the most inclusive registrational program to date in TED. To register, click here.
ACELYRIN Chief Executive Officer Mina Kim, Chief Medical Officer Dr. Shep Mpofu and Chief Commercial Officer Ken Lock will be joined by Drs. Andrea Kossler of the Stanford University School of Medicine and Prem Subramanian of the University of Colorado School of Medicine, both members of ACELYRIN's Scientific and Patient Advisory Boards. A live question and answer session will follow the formal presentations and a recording of the webcast will be available and archived on the Company's website for approximately 30 days.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment